Skip to content

Effects of a single dose of esketamine on the prevention and treatment of perinatal depression in cesarean delivery women after delivery of the fetus

Effects of a single dose of esketamine on the prevention and treatment of perinatal depression in cesarean delivery women after delivery of the fetus

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060313
Enrollment
Unknown
Registered
2022-05-28
Start date
2022-05-15
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perinatal depression

Interventions

Control group:After the fetus is delivered and the umbilical cord is clipped, intravenous injection of normal saline 0.1 mg/kg
Experimental group:After the fetus was delivered and the umbilical cord was clipped, intravenous esketamine 0.5 mg/kg was administered

Sponsors

The First Affiliated Hospital of USTC Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. The parturient is voluntary and signs the informed consent; 2. ASA: Level II-III; 3. Planned cesarean section 4. Maternal age: 20 years old 80 x 10^9/L, no obvious abnormality in coagulation function, or PT prolongation < 3 s, APTT prolongation < 10 s.

Exclusion criteria

Exclusion criteria: 1. Psychoneurotic drugs have been used before surgery; 2. Patients with serious or unstable heart, liver, kidney, endocrine, blood, and other internal diseases; 3. Inability to independently understand and complete the contents of the scale; 4. Those with severe depressive symptoms (such as suicidal ideation) require immediate antidepressant treatment.

Design outcomes

Primary

MeasureTime frame
Edinburgh Postnatal Depression Scale (EPDS);

Countries

China

Contacts

Public ContactLizhen Wang

The First Affiliated Hospital of USTC Anhui Provincial Hospital

ahwanglizhen@163.com+86 15155513602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026